Peptyde Bio emerged in 2022 as the first company to come out of the Donald Danforth Plant Science Center‘s Danforth Technology Company. From the get-go, a quick exit seemed possible, Tom Laurita, CEO of Danforth Technology Company and interim CEO of Peptyde Bio, tells AgFunderNews.
“We knew when we founded the company that there were several factors working in favor of a quick exit: a strong technology and IP base; support from the Danforth Center; the ability to attract top talent as a Danforth startup; and emerging consensus in industry that peptides represent a major opportunity.”
“That said, there was no certainty that all factors would work together so quickly, so we were ready to grow Peptyde Bio patiently through fund raise rounds,” he adds.
Yajie Niu, chief science officer at Invaio, says her company has been monitoring Peptyde Bio’s progress “for some time” and was very interested in the startup’s peptide-discovery research.
“We could see the potential for our combined complimentary approaches to accelerate the development of biological solutions for crop pests and disease,” she tells AgFunderNews. READ MORE